Treatment of Cognitive and Learning Impairment
AssigneeInstituto Superiore di Sanita
InventorsGiovanni Diana, Carla Fiorentini
Life of this patent
Estimating the term…
Abstract
Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders.
Claims20
Use of a Rho GTPase activator in the manufacture of a medicament for the treatment of learning and cognitive disorders, wherein the Rho GTPase activator is selected from CNF1, CNF2, DNT or a mutant or variant thereof, provided that the Rho GTPase activator is effective either to deamidate or to transglutaminate Gln63 in RhoA and/or Gln61 in Rac1 and/or Gln61 in CDC42.
A bacterial Rho GTPase activator that is capable of deamidating or transglutaminating Gln63 in RhoA (SEQ ID NO. 4) and/or Gln61 in Rac1 (SEQ ID NO. 5) or CDC42 (SEQ ID NO. 6), or homologues having at least 90% sequence homology thereto whilst retaining said amino acids.
An activated Rho-GTPase, selected from RhoA (SEQ ID NO. 4) where Gln63 is deamidated or transglutaminated, and Rac1 (SEQ ID NO. 5) and CDC42 (SEQ ID NO. 6) where Gln61 is deamidated or transglumated.
A method for treating learning or cognitive disorders in a patient comprising administering a Rho GTPase activator selected from CNF1, CNF2, DNT or a mutant or variant thereof, provided that the Rho GTPase activator is effective either to deamidate or to transglutaminate Gln63 in RhoA and/or Gln61 in Rac1 and/or Gln61 in CDC42.
Dependencies are inferred from the claim text.